A tablet, two injections and a branded line, all priced in public
The homepage carries four product tiles, each with a figure and a stock label: a dissolvable tablet taken once a day, a weekly injection, a weekly dual-incretin injection, and branded Ozempic. Nothing is gated behind a quiz.
The tablet is the reason to read this row. Oral GLP-1 therapy is thinly represented here, and the tablet is priced identically to the weekly injection rather than at a premium.
The branded line sits on the same screen as the compounded ones, which makes the gap between the two channels legible without doing any work.
The tiles do not name the drug
Three of the four tiles say only GLP-1, or GLP-1 plus GIP. Semaglutide and tirzepatide are named on the policy pages, and the brand names of four approved products appear in a trademark disclaimer, but none of that is attached to a price.
We therefore file those three figures under an unspecified GLP-1 rather than assigning them to a molecule. A dual-incretin injection is very probably tirzepatide; probably is not a fact, and a price filed under the wrong drug is worse than a price filed under none.
The branded tile is the exception: it names Ozempic, and a brand name identifies its molecule.
An edit that was published rather than applied
One FAQ answer on the live homepage reads as the original sentence, a closing quotation mark, the words Replace with, and then the replacement sentence. Both versions are visible to any reader.
The edit itself is small and telling: it removes a claim that the dispensing pharmacy is FDA-regulated. That is the kind of wording a company changes after a regulator writes to it about misleading claims, and this seller did receive such a letter in June 2026.
We record it because it is a live, reader-visible defect on the page a buyer reads before paying, not because of what it implies.
Flat, or starting at
A list of reasons to choose the service includes flat pricing that never goes up as the dose increases. Every figure below it is labelled as a starting point.
Those are two different promises about the same numbers, and the page makes both. Until the seller resolves it, the figures here are recorded as floors, with its flat-pricing claim noted against them.
No membership statement appears anywhere. The site says there are no long-term commitments, no cancellation fees and no hidden fees, none of which says whether a membership exists.
VivioMD's published pricing
| Medication | Price | Verified |
|---|---|---|
| Glp-1 (compounded-oral) | $299/mostarting at, per month — the seller's own "Starting at $299/mo" beside the tile "Personalized Care: GLP-1 Tablets"; ⛔ the priced tile names no molecule, so this figure is filed under GLP-1 and not under semaglutide | September 2026source |
| Glp-1 (compounded) | $299/mostarting at, per month — "Starting at $299/mo" beside "Personalized Care: GLP-1 Injections"; ⛔ the priced tile names no molecule | September 2026source |
| Glp-1 (compounded) | $398/mostarting at, per month — "Starting at $398/mo" beside "Personalized Care: GLP-1+GIP Injections"; ⛔ the priced tile names no molecule, so this is not filed under tirzepatide even though the combination implies it | September 2026source |
| Semaglutide (brand) | $1,299/mostarting at, per month, for the branded product — the seller prints "Starting at $1,299/mo" under "Ozempic® Injection" and adds on the same tile "Availability is subject to change." | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 264 providers reviewed here are paid partners today; the other 260 are not. See how this works.
See VivioMD's current price →Good fit if
- Readers who want a daily tablet instead of a weekly injection and want to see what it costs first.
- Buyers comparing a compounded lane against a branded one without starting an intake.
- People who want the operating company, the clinical group and the software platform named separately.
Look elsewhere if
- Anyone who needs to know which molecule they are buying before they pay.
- Buyers who need the compounding pharmacy named.
- Readers who want a figure that will not move as the dose rises, given that the site makes both claims.
- Anyone who wants a stated position on whether a membership fee applies.
How this review was verified
- Read the homepage and the privacy policy on 7 September 2026, comparing requested to effective URLs, with a nonsense path on the same host in the same run, which returned a 404.
- Took every figure from the homepage tile that carries it, with the tile's own label, so that a figure with no molecule beside it was recorded as having none.
- Checked the page for the promotional banner an earlier research file recorded and found it gone, so it is not carried here.
- Read the FAQ block in full and quoted the unexecuted edit from the extracted page text rather than describing it second hand.
- Screened the live FDA warning-letter datatable by entity name with a positive control returning exactly one row and a nonsense control returning none, then fetched the letter and confirmed its body names this seller's domain.